ArQule, Inc. (ARQL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule, Inc. (ARQL)

ARQL 20.00

0.0%

Jan 16 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (538)	9/5/2013 10:36:21 AM
From: tuck	Read Replies (2) of 545

And now they've had to lower the dose by 50% due to neutropenia. Considering it's early in the enrollment, they should not have more patients than they did in the P2 from which they derived the dose. While MET-high patients may not tolerate such AE's as well, it was those patients in which Tiva looked relatively good, so this is problematic, and not a good sign at all. Can Tiva hit MET hard enough at the new lower dose? Company probably has a bit of data from previous dose reduction in individuals, but investors do not. Might be worth a bet on upcoming ESMO data, but odds of success in 2nd line HCC look rather low. Of course, readout is 3 years away, so the current punishment might be another trading op. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next